Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Premier Inc. to Report Fiscal 2020 Second-Quarter Results and Host Conference Call Before Market Opens on February 4
Premier Inc. to Report Fiscal 2020 Second-Quarter Results and Host Conference Call Before Market Opens on February 4


Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 second-quarter financial results the morning of Feb. 4, 2020, followed by a conference call at 8 a.m. ET to discuss the results.



Conference

Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom


Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)

QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results
QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans as previously announced to release its report on results for the fourth quarter and full-year 2019 on Tuesday

Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!
Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!

Zu einem regelrechten Kursfeuerwerk kam es gestern bei der Aktie von Applied Genetic Technologies (WKN: A110V2), der Kurs konnte sich gestern von 4,16 auf 9,27 USD mehr als verdoppeln.

Grund für

Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the

Quidel Announces Preliminary Revenue for Fourth Quarter 2019
Quidel Announces Preliminary Revenue for Fourth Quarter 2019


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Hanger Announces Dates of 2019 Fourth Quarter Earnings Release and Conference Call
Hanger Announces Dates of 2019 Fourth Quarter Earnings Release and Conference Call


Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the fourth quarter and year

QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony
QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony


QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the 2,500th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories

QIAGEN feiert mehr als 2.500 QIAsymphony-Platzierungen
QIAGEN feiert mehr als 2.500 QIAsymphony-Platzierungen


QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) gab heute in Tübingen die 2.500. Platzierung eines QIAsymphony Geräts bekannt, der führenden Automatisierungslösung für „Sample to

Morphosys: Beste Perspektiven
Morphosys: Beste Perspektiven

Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.

Der Initiation der Phase 1-Studie von Tafasitamab

Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer


Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform

Evotec: Es regnet Millionen dank Bayer – wieder mal!
Evotec: Es regnet Millionen dank Bayer – wieder mal!

Vor zwei Tagen machte Evotec (WKN: 566480) die Erweiterung seiner iPSC-Allianz mit Bristol-Myers Squibb öffentlich (wir berichteten). Heute meldet der Hamburger Biotechkonzern eine „neue

Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions
Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today

Healthcare Improvement Company Premier Inc. to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14
Healthcare Improvement Company Premier Inc. to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that its Chief Executive Officer, Susan DeVore, will present at the 38th Annual J.P. Morgan Healthcare

Application Process for 2020 Louisville-Based Community Partners Program Opens
Application Process for 2020 Louisville-Based Community Partners Program Opens


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 38 years, today announced the details of its 2020 Community Partners Program. Through this initiative, The Humana

Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases

Veeva Introduces New Application to Speed Payments to Clinical Research Sites
Veeva Introduces New Application to Speed Payments to Clinical Research Sites


Veeva Systems (NYSE:VEEV) today introduced Veeva Vault Payments, a new add-on application for Veeva Vault CTMS that manages the payment and reimbursement process to clinical research sites. Vault

Veeva SiteVault Free Now Available to Simplify Study Execution at Clinical Research Sites
Veeva SiteVault Free Now Available to Simplify Study Execution at Clinical Research Sites


Veeva Systems (NYSE:VEEV) today announced the availability of Veeva SiteVault Free, a free eRegulatory solution for clinical research sites. Veeva SiteVault replaces manual and paper-based

Evotec: Das hören Anleger gern
Evotec: Das hören Anleger gern

Es sind Meldungen wie diese, die Anleger in Evotec-Aktien (WKN: 566480) jubeln lassen. Wie gestern bekannt gegeben, erweitert Evotec die Forschungsallianz mit dem Global Player Bristol-Myers Squibb

Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update


Regulatory News:



“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein